Search

Baozhu Zhang,1,* Haibo Wu2,* 1Department of Oncology, The People’s Hospital of Baoan Shenzhen, The Affiliated Baoan Hospital of Southern Medical University, Shenzhen, Guangdong 518101, People’s Republic of China; 2Department of Medical Administration, The People’s Hospital of Baoan Shenzhen, The Affiliated Baoan Hospital of Southern Medical University, Shenzhen, Guangdong 518101, People’s Republic of China *These authors contributed equally to this work Purpose: Collectin subfamily member 10 (COLEC10) encodes for collectin liver 1 (CL-L1), which is highly expressed in normal liver. Nevertheless, the association between COLEC10 and the prognosis of patients with hepatocellular carcinoma (HCC) remains unclear. To address this question, the prognostic value of COLEC10 expression in HCC was explored in this study. Patients and methods: Data from The Cancer Genome Atlas were used to compared transcriptional levels of COLEC10 in HCC samples and samples from healthy controls. In addition, COLEC10 mRNA and protein expression levels were analyzed in HCC tissue samples from Chinese patients and matched adjacent nontumorous tissue samples, by quantitative reverse-transcription polymerase chain reaction and immunohistochemistry, respectively. The prognostic value of COLEC10 was further examined using the Gene Expression Profiling Interactive Analysis online tool. Results: Both the mRNA and protein levels of COLEC10 were found to be downregulated in HCC tissues compared with normal controls. Survival analysis indicated that decreased mRNA and protein levels of COLEC10 were related with shorter overall survival in patients with HCC. In addition, univariate and multivariate analysis demonstrated that COLEC10 is an independent prognostic factor for overall survival of HCC patients. Conclusion: Together, the results suggest that decreased expression of COLEC10 may predict poor overall survival in patients with HCC. Keywords: collectins, survival analysis, liver neoplasms, CL-L1

Background Ubiquitin specific peptidase 14 (USP14), a deubiquitinating enzyme, has been documented as a key element to regulate the proteolysis function of proteasomes and an attractive therapeutic target for several cancers. Herein, we elucidate the role of USP14 in predicting the prognosis of patients with esophageal squamous cell carcinoma (ESCC). Methods USP14 expression was detected in ESCC tissues and matched adjacent non‐tumorous tissues by quantitative real‐time reverse transcription‐PCR and immunohistochemistry. Kaplan–Meier survival analysis was used to assess the correlation between USP14 expression and prognosis in ESCC patients. Univariate and multivariate analysis was conducted with a Cox proportional hazards model to determine whether USP14 is an independent prognostic factor. Result Overexpression of USP14 was observed in approximately 60% of tested ESCC samples compared to their paired non‐tumor esophageal tissues at both RNA and protein levels, and was significantly associated with distant metastasis (P = 0.001). Kaplan–Meier analysis showed that USP14 overexpression was related to poorer overall patient survival. Univariate and multivariate analyses demonstrated that USP14 was an independent risk factor for overall survival. Conclusion The findings in this study suggest that USP14 could be used as a potential prognostic marker for ESCC patients.